Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.

##plugins.themes.academic_pro.article.sidebar##

Published Apr 6, 2024
https://doi.org/10.62438/tunismed.v102i4.4688
Download
PDF
Vol. 102 No. 4 (2024): Tunis Med apr 2024

##plugins.themes.academic_pro.article.main##

Oussama Aazzane
Laboratory of cellular and molecular pathology,Immunology laboratory, Faculty of medicine and pharmacy, Hassan II university of Casablanca, Laboratory of pathological anatomy and cytology, CHU Ibn Rochd of Casablanca, Morocco.
Fatima Zahra Bakhtaoui
Laboratory of pathological anatomy and cytology, CHU Ibn Rochd of Casablanca, Morocco
Saida Stitou
Laboratory of pathological anatomy and cytology, CHU Ibn Rochd of Casablanca, Morocco
Hassan Fellah
Laboratory of cellular and molecular pathology,Immunology laboratory, Faculty of medicine and pharmacy, Hassan II university of Casablanca, Morocco
Mehdi Karkouri
Laboratory of cellular and molecular pathology,Faculty of medicine and pharmacy, Hassan II university of Casablanca, Laboratory of pathological anatomy and cytology, CHU Ibn Rochd of Casablanca, Morocco.

Abstract

Aim: Our study aimed to perform on Moroccan patients non-small cell lung carcinoma (NSCLC) concerning the relationship between PD-L1 tumor expression, clinicopathological features and tumor infiltrating immune cells (ICs).


Methods: This is a retrospective study (2019 to 2021) conducted on samples from Moroccan patients with NSCLC at the Pathological Anatomy Laboratory of Ibn Rochd University Hospital in Casablanca. Eligible participants for our study had to meet the following predefined criteria: age ≥18 years, histologically confirmed NSCLC, no prior therapeutic interventions, availability of clinical and pathological data, and a usable tumor sample for determining PD-L1 status. Exclusion criteria applied to patients with other types of lung cancer and unusable tumor samples. The evaluation of tumor and immune expression of PD-L1 was performed using immunohistochemistry (IHC), with the 22C3 clone on the Dako Autostainer Link 48 platform. Tumor PD-L1 expression was categorized into 3 levels: TPS <1% (negative expression), TPS 1-49% (low expression), and TPS ≥50% (high expression). ICs infiltrating the tumor expressing PD-L1 were considered positive when more than 1% of positive ICs were present.


Results:
Among the 316 analyzed samples, 56.6% showed a negative expression of PD-L1, 16.8% displayed a low expression of PD-L1, and 26.6% exhibited a strong expression. Regarding the histological type, among patients with TPS ≥ 50%, 25.8% had adenocarcinoma. Among patients with TPS ≥ 50%, 24.81% were smokers. PD-L1 was also strongly expressed in the lung (28.2%) and bronchi (26.5%). PD-L1 expression (TPS ≥ 50%) was observed   ...( abstract truncated at 250 words).

Keywords:

Non-small cell lung cancer, PD-L1, immunohistochemistry., tumor-infiltrating immune cells

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. International agency for research on cancer. Morocco. Globocan 2020.
  2. Available from: https://gco.iarc.fr/today/data/factsheets/populations/504-morocco- factsheets.pdf.
  3. Anna G, Kamila W, Ewa K. Beyond PD-L1 Markers for Lung Cancer Immunotherapy. International Journal of Molecular Sciences 2019;20(8):1915. DOI: 10.3390/ijms20081915.
  4. Seung Eun L, Yu Jin K, Minjung S, Mi-Sook L, Joungho H. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single- Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. International Journal of Molecular Sciences 2019;20(19):4794. DOI: 10.3390/ijms20194794.
  5. Planchard D, Popat S, Kerr K. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 29 2018; 29 (Suppl. 4). DOI:10.1093/annonc/mdy275.
  6. Hui Y, Zhengming C, MPH, Karla V. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. Journal of Thoracic Oncology 2018;14(1):25-36. DOI: 10.1016/j.jtho.2018.09.006.
  7. Schoenfeld J, Rizvi H, Bandlamudi C. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology 2020; 31(5):599- 608. DOI.org/10.1016/j.annonc.2020.01.065.
  8. Gen L, Xirong F, Weifeng Z, Cheng H. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget 2017;8(48):83986-83994. DOI: 10.18632/oncotarget.20233.
  9. Yan J, Xuxia S, Yunjian P, Qiang Z. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. Journal of Thoracic Disease 2019;11(11):4591-4601. DOI: 10.21037/jtd.2019.10.80.
  10. Mino-Kenudson M. Programmed cell death ligand-1 (PDL1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med 2016 ;13(2):157-70. DOI: 10.20892/j.issn.2095-3941.2016.0009.
  11. Yanqing L, Aihua W, Xinjian L, Shanshan W. A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients. Asian Journal of Surgery 2022;45(1):367-375. DOI: 10.1016/j.asjsur.2021.06.030.
  12. Kathrin G, Lukas K, Julian T, Chukwuka E. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology 2020
  13. ;15(1):5.DOI: 10.1186/s13014-019-1453-3.
  14. Andreas H. Scheela, Sascha Ans, Anne M. PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Onco-immunology 2016;5(5):e1131379. DOI: 10.1080/2162402X.2015.1131379.
  15. Peng S, Lei G, Wenbin L. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer. Journal Immunotherapy 2019;42(1):23-28. DOI: 10.1097/CJI.0000000000000249.
  16. Tsao M, Kerr K, Kockx M. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology 2018 ;13(9):1302-1311. DOI: 10.1016/j.jtho.2018.05.013.
  17. Mithoowani H, Febbraro M. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Current Oncology 2022 ; 9;29(3):1828- 1839. DOI: 10.3390/curroncol29030150.
  18. PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC. Agilent-Dako. Available from: https://www.agilent.com/cs/library/usermanuals/public/29158_pd- l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf, 2022 (Accessed on 15/09/2022).
  19. Sylvie L, Julien A, Nicolas G. PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists. Annales de pathologie 2018. doi.org/10.1016/j.annpat.2018.01.007.
  20. Antonio C, Xiaoyun L, Lynette M. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Journal of thoracic oncology 2015. doi.org/10.1097/JTO.0000000000000687.
  21. Ming Y, Mengke N, Linping X. Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology and Oncology 2021. doi.org/10.1186/s13045-020-01027-5.
  22. Lamberti G, Sisi M, Andrini E. The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players. Cancers 2020. doi: 10.3390/cancers12113129.
  23. Matthew E, Brendan O, Frances H. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. Pathology & Oncology Research 2018. doi.org/10.1007/s12253-018-0469-6.